-
公开(公告)号：WO2023085973A1
公开(公告)日：2023-05-19
申请号：PCT/RU2022/000335
申请日：2022-11-14
Inventor： САМСОНОВ, Алексей Алексеевич , ШМЕЛЕВА, Варвара Николаевна , ГОЛУБЕВА, Наталья Александровна
Abstract: Изобретение относится к области медицины и химико-фармацевтической промышленности, а именно к улучшенным субстанциям грамицидина С, содержащих определенные количества новых циклических декапептидов из семейства грамицидинов С, а также к содержащим их фармацевтическим композициям для лечения инфекционно-воспалительных заболеваний.
-
公开(公告)号：WO2023081318A2
公开(公告)日：2023-05-11
申请号：PCT/US2022/048890
申请日：2022-11-03
Applicant: APELLIS PHARMACEUTICALS, INC.
Inventor： FRANCOIS, Cedric , DESCHATELETS, Pascal , GROSSI, Federico
Abstract: Complement is an arm of the innate immune system that plays an important role in defending the body against infectious agents. Although compositions that inhibit complement are known, there remains a need for compositions that can acutely inhibit complement. Methods and compositions comprising PEGylated compstatin analog for inhibiting complement are described.
-
公开(公告)号：WO2023039206A2
公开(公告)日：2023-03-16
申请号：PCT/US2022/043127
申请日：2022-09-09
Applicant: APELLIS PHARMACEUTICALS, INC.
Inventor： FRANCOIS, Cedric , DESCHATELETS, Pascal , GROSSI, Federico
Abstract: Methods and compositions for treatment of geographic atrophy are described.
-
公开(公告)号：WO2023025266A1
公开(公告)日：2023-03-02
申请号：PCT/CN2022/114979
申请日：2022-08-26
Applicant: 丹诺医药（苏州）有限公司
IPC: A61K31/439 , A61K31/43 , A61K45/06 , A61K38/12 , A61K31/65 , A61P31/04 , A61P11/00 , A61P7/00 , A61P17/00 , A61P13/00 , A61P25/28
Abstract: 本申请涉及一种药物组合物，其包含舒巴坦或其药学上可接受的盐和阿维巴坦或其药学上可接受的盐，其中，所述舒巴坦或其药学上可接受的盐和所述阿维巴坦或其药学上可接受的盐的单位剂量比为约8:1-约4:1，所述舒巴坦或其药学上可接受的盐的单位剂量为约1-4g，所述阿维巴坦或其药学上可接受的盐的单位剂量为约0.125-1g，以及任选地药学上可接受的载体。本申请还涉及使用所述药物组合物治疗细菌感染的方法。
-
公开(公告)号：WO2023012280A1
公开(公告)日：2023-02-09
申请号：PCT/EP2022/071960
申请日：2022-08-04
Applicant: ZAMBON S.P.A.
Inventor： CASTELLANI, Paola
Abstract: The present invention relates to the use of Colistin for reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), wherein said patients are infected with P. aeruginosa.
-
Patent Agency Ranking6.发明申请
公开(公告)号：WO2023000038A1
公开(公告)日：2023-01-26
申请号：PCT/AU2022/050778
申请日：2022-07-22
Applicant: LATERAL IP PTY LTD
Inventor： GEARING, Andrew , KENLEY, David
IPC: A61K38/00 , A61K38/12 , A61P11/00 , A61P25/02 , A61P31/14 , C07K5/09 , C07K5/11 , C07K7/06 , C07K7/08
Abstract: The present invention provides various peptide compositions capable of binding Lanthionine synthetase C-like protein (LanCL) that have analgesic, anti-inflammatory and anti-microbial properties.The compositions comprise a peptide formula (I): X1-X2-X3- X4-X5-X6, wherein X represents specific groups of amino acids, and the peptide is 3-20 amino acids in length, it does not comprise sequences CRSRPVESSC, CRSVEGSCG, or CRIIHNNNC and is not a linear peptide comprising the sequence EQLERALNSS.
-
公开(公告)号：WO2023288017A2
公开(公告)日：2023-01-19
申请号：PCT/US2022/037202
申请日：2022-07-14
Applicant: JANSSEN BIOTECH, INC. , PROTAGONIST THERAPEUTICS, INC.
Inventor： SUN, Chengzao , NEELAMKAVIL, Santhosh , PATCH, Raymond, J. , SOMANI, Sandeep , BARROS, Stephanie, A. , ZHANG, Jing , HENDRICK, Charles , BIANCHI, Elisabetta , COSTANTE, Roberto , INGENITO, Raffaele , BRANCA, Danila , BHANDARI, Ashok , FREDERICK, Brian , TRAN, Tran Trung , ZHANG, Jie
IPC: C07K7/54 , A61K38/12 , A61P19/02 , A61K38/00 , A61P29/00 , A61P37/00 , C07K7/06 , C07K7/08 , C07K7/56
Abstract: The present invention relates to novel bicyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
-
公开(公告)号：WO2022265481A1
公开(公告)日：2022-12-22
申请号：PCT/KR2022/095079
申请日：2022-04-07
Applicant: 주식회사 오리엔트바이오
Abstract: 본 발명은 사이클로스포린 3위치 유도체 및 생분해성 고분자를 포함하는 입자, 이를 포함하는 방출조절형 국소주사용 조성물, 및 이의 탈모예방 및 발모촉진 용도에 관한 것이다.
-
公开(公告)号：WO2022261257A1
公开(公告)日：2022-12-15
申请号：PCT/US2022/032738
申请日：2022-06-08
Applicant: FOG PHARMACEUTICALS, INC.
Inventor： WHITE, Brian Halbert , LA, Daniel Seungduk , ALFARO-LOPEZ, Lorenzo Josue , ORTET, Paula Cristina , CAPPUCCI, Sarah Isabelle , LI, Zhi , MCGEE, John Hanney , TREMBLAY, Martin Robert , VERDINE, Gregory L. , SI, Yaguang , LING, Kevin , DU, Peicheng , HUROV, Jonathan Barry
Abstract: Among other things, the present disclosure provides various useful agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids and agents which can provide improved properties and/or activities.
-
公开(公告)号：WO2022236003A1
公开(公告)日：2022-11-10
申请号：PCT/US2022/028002
申请日：2022-05-06
Applicant: LYTICA THERAPEUTICS, INC.
Inventor： MOURTADA, Rida , DORSCH, Warren, A.
IPC: C07K14/435 , A61K38/12 , A61P31/04
Abstract: Provided are stapled antimicrobial peptides (i.e., StAMPs) and methods of using the same (e.g., for treating bacterial infections caused by Gram-negative bacteria). In certain embodiments, the stapled peptides are based on the amino acid sequence of the antimicrobial peptide Esculentin-1A but include certain modifications that have been found to confer advantageous properties (e.g., improved antimicrobial activity, selectivity for killing Gram-negative bacteria, and/or reduced toxicity). Also provided are unstapled peptides which can serve as synthetic precursors to the stapled peptides provided herein.
-
-
-
-
-
-
-
-
-
Search Results
1628
records
(took 0.038 seconds)
